ArticleBMC rheumatology2026
Metabolomics and cardiovascular risk factors in autoimmune-mediated connective tissue diseases - an exploratory, hypothesis-generating study.
Article in BMC rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutoimmune connective tissue diseases (ACTD), including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's disease (SD), and idiopathic inflammatory myopathies (IIM), are associated with markedly increased cardiovascular risk (CVR) that is insufficiently captured by conventional risk scores. Reliable biomarkers for CVR stratification in ACTD are lacking. This exploratory, hypothesis-generatig study aimed to investigate whether metabolomic alterations reflect CVR across ACTD subtypes.
methodsIn this cross-sectional, exploratory study, patients with SLE (n = 33), SSc (n = 18), SD (n = 16), and IIM (n = 9) were recruited from a tertiary rheumatology center. Serum metabolomic profiling was performed using ¹H-NMR spectroscopy. Associations between 113 quantified metabolites and clinical CVR parameters (including age, sex, body mass index, glucocorticoid use, Framingham score, hypertension, diabetes, lipid parameters, and lifestyle factors) were analyzed using non-parametric statistics with false discovery rate correction. Correlation analyses were conducted using Spearman coefficients.
resultsMetabolomic alterations varied substantially across ACTD subtypes and CVR factors. Lipid metabolites showed the strongest and most consistent associations with CVR parameters. The Framingham score correlated with 11 metabolites in SLE, 1 in SSc, 2 in SD, and 93 in IIM, predominantly involving lipid components. Diabetes mellitus was associated with extensive metabolomic changes, particularly in SSc (n = 62 metabolites), followed by SD (n = 20) and SLE (n = 5). In contrast, arterial hypertension showed minimal metabolomic differentiation across most ACTD, except in IIM. Body mass index correlated mainly with lipid metabolites in SSc, but not in SLE. Glucocorticoid therapy and dosage were strongly associated with alterations in lipid metabolism, especially in SLE and SSc. Across all entities, correlations with total cholesterol, LDL, and HDL were dominated by lipid metabolites. Associations with renal markers (UACR) were limited.
conclusionsACTD are characterized by heterogeneous metabolomic signatures associated with cardiovascular risk factors. Larger, longitudinal studies are required to validate these findings and to determine their clinical utility in cardiovascular risk stratification in ACTD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.